Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | PRKACA | P17612 | 2/20 | 0.46 |
| ▸ | CDK8 | P49336 | 2/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 7/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.45 |
| ▸ | RET | P07949 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16372078 | 0.98 | DYRK1A (0.50) | DYRK1AKDM4ECLK4MAPK14MAP4K4 | |
| SCHEMBL3500436 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL2067916 | 0.74 | DYRK1A (0.52) | DYRK1AKDM4ECLK4MAPK14MAP4K4 | |
| SCHEMBL16875635 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL5487802 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL7514132 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL9125832 | 0.74 | KDR (0.62) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL1051267 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL4560704 | 0.74 | DYRK1A (0.52) | DYRK1ACLK4MAPK14MAP4K4PRKACA | |
| SCHEMBL877547 | 0.74 | DYRK1A (0.47) | DYRK1ACLK4MAPK14MAP4K4PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 732 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116282949-B | Glass through hole copper electroplating solution for radio frequency device and copper electroplating process thereof | 深圳创智芯联科技股份有限公司 | 2024-11-12 | — | — | CN | claimed |
| CN-116282949-A | Glass through hole copper electroplating solution for radio frequency device and copper electroplating process thereof | 深圳创智芯联科技股份有限公司 | 2023-06-23 | — | — | CN | claimed |
| EP-4719597-A1 | SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED CALCIUM ION CHANNEL CAV2.3 ANTAGONISTS | Lario Therapeutics Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4683909-A2 | ATM KINASE INHIBITORS | Eberhard Karls Universität Tübingen (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-12534469-B2 | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2026-01-27 | — | — | US | disclosed |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260015328-A1 | ATM KINASE INHIBITORS | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2026-01-15 | — | — | US | disclosed |
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250340557-A1 | PYRIMIDINE DERIVATIVE | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2025-11-06 | — | — | US | disclosed |
| US-20250304558-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-10-02 | — | — | US | disclosed |
| EP-0381132-A1 | Imidazopyridazines, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-08-08 | — | — | EP | disclosed |
| US-4942159-A | ANTIBIOTICS, BACTERICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-07-17 | — | — | US | disclosed |
| US-4921851-A | Cephem compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| US-4864022-A | 3-Condensed imidazolium-cephem compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0304858-A2 | Cephem compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-03-01 | — | — | EP | disclosed |
| EP-0249170-A2 | Cephem compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-12-16 | — | — | EP | disclosed |
| EP-0229369-A2 | Cephalosporins, process for their preparation and pharmaceutical compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1987-07-22 | — | — | EP | disclosed |
| EP-0203271-A2 | Antibacterial compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-12-03 | — | — | EP | disclosed |
| WO-1986005183-A1 | ANTIBACTERIAL COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | RYR2, CACNA1C, CAMK4 | DYRK1A 1528/4885KDM4E 4364/4885CLK4 910/4885 |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | DYRK1A 18/4885KDM4E 2135/4885CLK4 4/4885 |
| US-20250340557-A1 | PYRIMIDINE DERIVATIVE | PTGES, PTGS1, PTGIS | DYRK1A 4220/4885KDM4E 3195/4885CLK4 4399/4885 |
| US-20260015328-A1 | ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | DYRK1A 767/4885KDM4E 2112/4885CLK4 218/4885 |
| US-12534469-B2 | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | FLT3, IRAK3, IRAK2 | DYRK1A 2786/4885KDM4E 607/4885CLK4 1756/4885 |
| US-20250304558-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, KCNH1 | DYRK1A 3936/4885KDM4E 1095/4885CLK4 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.